Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024 16:30 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 31, 2024 07:00 ET
|
Fulcrum Therapeutics, Inc.
― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― ― Entered into a collaboration and ex-U.S....
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
July 24, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 12, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 06, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024 07:00 ET
|
Fulcrum Therapeutics, Inc.
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024 06:00 ET
|
Fulcrum Therapeutics, Inc.
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment...
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 09, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 08, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3...
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
May 06, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...